Effect of ocular compression on intraocular penetration of systemic ofloxacin

Intraocular levels of ofloxacin are documented after topical and systemic administration, but systemic administration of ofloxacin in ocular compression has not yet been studied. This study was undertaken to determine the intraocular penetration of systemic ofloxacin into aqueous and vitreous humor after the application of ocular compression in rabbit eyes. Ocular compression with the Honan balloon was applied for 30 min to the right eyes of 11 albino New Zealand white rabbits. After the application of ocular compression, 2 mg/mL of ofloxacin was administered intravenously. Samples from aqueous and vitreous humor were collected 30 min after infusion. Ofloxacin concentrations were determined through high-performance liquid chromatography. The mean aqueous level of ofloxacin was significantly higher in the compression group (2.40±1.00 µg/mL) than in the no-compression group (1.61±1.06 µg/mL) (P<.05). The mean vitreous concentrations of ofloxacin were 0.70±0.33 µg/mL and 0.50±0.18 µg/mL in the compression and no-compression groups, respectively. A significant difference was observed between vitreous ievels of ofloxacin in the compression and no-compression groups (P<.05). Ocular compression enhanced the penetration of ofloxacin in both aqueous and vitreous humor. The drug level in the aqueous humor was sufficient for the minimum inhibitory concentration for 90% of isolates (MIC 90) to inhibit most microorganisms. Although the mean vitreous ofloxacin concentration was increased by previous ocular compression, it was not sufficiently above the MIC 90 for most ocular pathogens that caused endophthalmitis. ©2007 Health Communications Inc.

Dergi Adı Advances in Therapy
Dergi Cilt Bilgisi 24
Dergi Sayısı 2
Sayfalar 394 - 401
Yayın Yılı 2007
Eser Adı
[dc.title]
Effect of ocular compression on intraocular penetration of systemic ofloxacin
Yazar
[dc.contributor.author]
Ugurbas S.H.
Yazar
[dc.contributor.author]
Can M.
Yazar
[dc.contributor.author]
Koksal M.
Yazar
[dc.contributor.author]
Dincel A.
Yazar
[dc.contributor.author]
Bozkurt A.
Yazar
[dc.contributor.author]
Bayar B.
Yayın Yılı
[dc.date.issued]
2007
Yayın Türü
[dc.type]
article
Özet
[dc.description.abstract]
Intraocular levels of ofloxacin are documented after topical and systemic administration, but systemic administration of ofloxacin in ocular compression has not yet been studied. This study was undertaken to determine the intraocular penetration of systemic ofloxacin into aqueous and vitreous humor after the application of ocular compression in rabbit eyes. Ocular compression with the Honan balloon was applied for 30 min to the right eyes of 11 albino New Zealand white rabbits. After the application of ocular compression, 2 mg/mL of ofloxacin was administered intravenously. Samples from aqueous and vitreous humor were collected 30 min after infusion. Ofloxacin concentrations were determined through high-performance liquid chromatography. The mean aqueous level of ofloxacin was significantly higher in the compression group (2.40±1.00 µg/mL) than in the no-compression group (1.61±1.06 µg/mL) (P<.05). The mean vitreous concentrations of ofloxacin were 0.70±0.33 µg/mL and 0.50±0.18 µg/mL in the compression and no-compression groups, respectively. A significant difference was observed between vitreous ievels of ofloxacin in the compression and no-compression groups (P<.05). Ocular compression enhanced the penetration of ofloxacin in both aqueous and vitreous humor. The drug level in the aqueous humor was sufficient for the minimum inhibitory concentration for 90% of isolates (MIC 90) to inhibit most microorganisms. Although the mean vitreous ofloxacin concentration was increased by previous ocular compression, it was not sufficiently above the MIC 90 for most ocular pathogens that caused endophthalmitis. ©2007 Health Communications Inc.
Kayıt Giriş Tarihi
[dc.date.accessioned]
2019-12-23
Açık Erişim Tarihi
[dc.date.available]
2019-12-23
Yayın Dili
[dc.language.iso]
eng
Konu Başlıkları
[dc.subject]
Blood-aqueous barrier
Konu Başlıkları
[dc.subject]
Blood-retina barrier
Konu Başlıkları
[dc.subject]
Intraocular concentration
Konu Başlıkları
[dc.subject]
Ocular compression
Konu Başlıkları
[dc.subject]
Ofloxacin
Haklar
[dc.rights]
info:eu-repo/semantics/closedAccess
ISSN
[dc.identifier.issn]
0741238X
Sponsor YAYINCI
[dc.description.sponsorship]
SBAG-COST B15-2356
Sponsor YAYINCI
[dc.description.sponsorship]
This study was supported by a grant from the Scientific and Technical Research Council of Turkey (SBAG-COST B15-2356).
İlk Sayfa Sayısı
[dc.identifier.startpage]
394
Son Sayfa Sayısı
[dc.identifier.endpage]
401
Dergi Adı
[dc.relation.journal]
Advances in Therapy
Dergi Sayısı
[dc.identifier.issue]
2
Dergi Cilt Bilgisi
[dc.identifier.volume]
24
Tek Biçim Adres
[dc.identifier.uri]
https://dx.doi.org/10.1007/BF02849909
Tek Biçim Adres
[dc.identifier.uri]
https://hdl.handle.net/20.500.12628/5351
Görüntülenme Sayısı ( Şehir )
Görüntülenme Sayısı ( Ülke )
Görüntülenme Sayısı ( Zaman Dağılımı )
Görüntülenme
23
09.12.2022 tarihinden bu yana
İndirme
1
09.12.2022 tarihinden bu yana
Son Erişim Tarihi
09 Şubat 2024 07:23
Google Kontrol
Tıklayınız
ofloxacin compression vitreous aqueous ocular no-compression systemic concentration concentrations Ocular µg/mL) application groups penetration administration µg/mL between ievels enhanced observed difference significant respectively Intraocular sufficient sufficiently Communications Health ©2007 endophthalmitis caused pathogens minimum previous increased
6698 sayılı Kişisel Verilerin Korunması Kanunu kapsamında yükümlülüklerimiz ve çerez politikamız hakkında bilgi sahibi olmak için alttaki bağlantıyı kullanabilirsiniz.

creativecommons
Bu site altında yer alan tüm kaynaklar Creative Commons Alıntı-GayriTicari-Türetilemez 4.0 Uluslararası Lisansı ile lisanslanmıştır.
Platforms